Skip to Main Content

Paper Details

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial.
Circulation
184
2021
Chronic Heart Failure, Diabetes, Empagliflozin, HbA1c, Heart Failure, Patients, Sodium, Sodium-glucose cotransporter 2, cardiovascular, diabetes, empagliflozin, glucose, heart failure, hemoglobin A1c, hypoglycemia, normoglycemia, patients, prediabetes, renal events
Author NameAffiliation
Gerasimos FilippatosNational and Kapodistrian University of Athens School of Medicine, Athens University Hospital Attikon
Carolyn S P LamNational Heart Centre Singapore & Duke-National University of Singapore (C.S.P.L.).
Sergio V PerroneHospital de Alta Complejidad El Cruce "Nestor Kirchner," Florencio Varela
Milton PackerBaylor University Medical Center
Milton PackerImperial College
  • 1 - 5

Datasets

Release 1.2